A New Milestone in Lactamo’s Clinical Evidence
We are proud to share the results of a recent independent trial conducted from April to July 2025 at the Amsterdam University Medical Centre (AUMC). Led by a team of 12 experienced lactation consultants, the study evaluated Lactamo’s immediate physiological impact on breast inflammation using an objective and highly regarded biomarker: sodium content in breastmilk.
During the trial, sodium levels were measured immediately before and immediately after a single use of Lactamo, with all other variables held constant. The aim was to quantify Lactamo’s effect in real time, under controlled, clinically relevant conditions.
The findings — a 24% reduction in sodium levels after one use — are both significant and unprecedented in this context.
Trial lead Elly Krijnen Ursem commented:
"Lactamo is an exciting breakthrough in breastfeeding innovation. The results are conclusive, and what is most exciting is that this is an easy and accessible solution that mothers can use themselves."
Why Sodium Matters as an Inflammation Marker
The link between elevated sodium in breastmilk and inflammation is well established. A landmark study by Perrella et al. (2022) demonstrated that sodium concentration and the sodium-to-potassium (Na:K) ratio are reliable, quantitative indicators of breast inflammation, including mastitis, blocked ducts, engorgement, and oversupply.
In their longitudinal research involving mothers of preterm infants, Perrella and colleagues observed that sodium levels were elevated during mastitis episodes and returned to normal within 48 hours of symptom resolution — regardless of whether infection was culture-confirmed. This positions sodium analysis as a real-time, objective tool for assessing breast health (PubMed link).
How the AUMC Trial Builds on Lactamo’s Clinical Validation
Previous studies have validated Lactamo’s clinical safety, efficacy, and user acceptability. The AUMC trial adds a new layer of quantitative biomarker evidence to that foundation:
-
Controlled measurement: same breast, before and after a single use of Lactamo
-
Significant change: 24% reduction in sodium concentration
-
Implication: measurable physiological impact on inflammation within minutes of use
By integrating objective biochemical data with patient-reported outcomes from earlier research, Lactamo’s body of evidence now spans both the lived experience of mothers and measurable biological changes.
Why This Matters to Healthcare Professionals
For healthcare providers, these findings are important for three reasons:
-
Evidence-based: supported by science and controlled clinical testing
-
Practical: a self-administered, non-invasive tool that mothers can use at home or in hospital settings, proactively and reactively
-
Impactful: capable of reducing inflammation quickly, potentially preventing progression to more severe conditions
This latest trial reinforces Lactamo’s role as a trusted, effective adjunct in the prevention and management of common breastfeeding complications — empowering mothers while providing clinicians with a solution supported by both clinical outcomes and biological markers.
Reference
Perrella, S., Anderton-May, E.-L., McLoughlin, G., Lai, C. T., Simmer, K. N., Geddes, D. T., & McKenna, L. J. (2022). Human milk sodium and potassium as markers of mastitis in mothers of preterm infants. Breastfeeding Medicine, 17(12), 1003–1010. https://doi.org/10.1089/bfm.2022.0198
